SATO PHARMACEUTICAL CO.,LTD. (E00954) Stock Price

Sato Pharmaceutical is a pharmaceutical company primarily focused on over-the-counter (OTC) medicines, offering a wide range of health-related products. The company handles everything from research and development to manufacturing and sales of OTC medicines (such as cold and gastrointestinal remedies) available without a prescription, as well as quasi-drugs, cosmetics, and food products. The company also operates a prescription pharmaceutical business, supplying specialized medicines to medical institutions.

The company's revenue structure consists of two main pillars: the OTC business serving general consumers and the pharmaceutical business serving medical institutions. In the OTC business, products are sold to consumers through retail channels such as pharmacies and drugstores. In the pharmaceutical business, prescription medicines are supplied to hospitals and clinics. The company is also actively expanding internationally, having established subsidiaries in Hong Kong, Singapore, the United States, Taiwan, Canada, and Germany to build a global sales network.

In its business segments, the OTC business is the primary driver, operating through a manufacturing and sales structure coordinated with nine domestic and international subsidiaries, including Kipp Pharmaceutical. In the pharmaceutical business, Medix Sato handles the sales of prescription medicines and builds relationships with medical institutions through specialized sales activities. The company maintains a stable domestic market foundation while pursuing growth opportunities through international market expansion.

Sato Pharmaceutical is pursuing a growth strategy built on two pillars: its healthcare business and pharmaceutical business. To enhance corporate value, the company manages operations with focus on sales revenue, operating profit, and operating profit margin. It aims to strengthen competitiveness and improve efficiency across business divisions by addressing demographic shifts toward an aging society, adapting to market structure changes, and advancing digitalization. As the self-care market is expected to expand, the company prioritizes developing products that meet emerging health needs and establishing strong brands resilient to market fluctuations.

In the healthcare business, the company is advancing a growth strategy centered on flagship brands including Yunkel, Stona, Aces, and Ringle. It is focusing on developing innovative products such as switch OTC and direct OTC medications, actively nurturing brands including the Nazal Series, Empecid L, and Arasena. On the sales front, the company is expanding market share across e-commerce platforms, strengthening promotional activities at major convenience stores, and reinforcing the Yunkel Royal Series in supermarkets and general merchandise retailers. It has also reorganized its sales structure to enable more efficient promotional activities.

In the pharmaceutical business, the company prioritizes dermatology as a key focus area, with plans to launch Luconac in Singapore from June to August 2024. It is preparing applications in the Philippines, Malaysia, and Thailand, while advancing Phase 2 trial preparations for a topical antifungal agent in the United States. Domestically, the company aims to become the leading company in the nail fungus market, deploying multifaceted promotional activities for Nailin and Luconac using digital channels, and expanding patient reach for the Emla Series, which has grown to the top market share in the topical local anesthetic market.

For international expansion, the company is pursuing sales growth in Hong Kong, Taiwan, and Singapore while strengthening its business foundation in Asia. It is preparing to enter the Indian market and advancing new product launches for its successful cosmetics brand Excelula in China alongside e-commerce infrastructure development. In North America, the company is strengthening sales through Amazon, while in Europe it continues building the Yunkel brand in Germany, aiming to establish a global growth platform. Additionally, the company plans to begin construction of a new manufacturing building at its Hachioji plant in 2025 and is committed to building a sustainable business foundation through carbon neutrality initiatives, including expanded solar power generation capacity.